Erkek meme kanseri

Erkek meme kanseri (EMK) nadir bir hastalıktır. Erkek-lerdeki tüm kanserlerin %1’den daha azı ve tüm meme kanserlerinin yaklaşık %1’ini oluşturur. Nadir bir hastalık olduğu için, ileriye dönük randomize bir çalışma yoktur ve bilgilerin çoğu tek merkezin geriye dönük çalışma-larına ya da kadın meme kanseri (KMK) çalışmalarına dayanır. Bu makalede erkek meme kanserinde insidans, etiyoloji, klinik özellikler, tanı, tedavi, patoloji, sağkalım ve prognostik faktörler sunulmuştur. EMK ve KMK ara-sında tanı sırasında yaş, evre, histolojik tip, moleküler belirteçler, steroid hormon reseptör ekspresyonu bakı-mından farklar vardır. Modifiye radikal mastektomi halen standart tedavidir, adjuvan radyoterapi sıklıkla uygulanır ve tamoksifen kullanılır. Genel olarak, ileri yaş, büyük tümör boyutu, aksiller lenf nodu metastazı varlığı, ileri evre, yüksek grad, negatif hormon reseptör olması EMK’da kötü prognoz ile ilişkilidir.

Male breast cancer

Male breast cancer (MBC) is a rare disease accounting for less than 1% of all cancers in men and comprises about 1% of all breast cancers. Because of its rarity, there have been no prospective randomized trials and most of data depends on small single institution retrospective studies or female breast cancer (FBC) trials. This article presents an overview of MBC with emphasis on incidence, etiology, clinical features, diagnosis, treatment, pathology, survival, prognostic factors. MBC and FBC contrast in the age at diagnosis, tumor stage, histological types, molecular markers, expression of steroid hormone receptor. Modified radical mastectomy remains the standard treatment, adjuvant radiotherapy is often performed and tamoxifen is used. Globally, older age, larger tumor size, axillary lymph node metastasis, advanced stage, higher grade, and hormone receptor negativity are associated with poor prognosis in MBC.

PDF

___

1. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World J Surg Oncol 2008;6: 58.
2. Giordano SH, Cohen DS, Buzdar AU, Perkins GP, Hortobagyi GN. Breast carcinoma in men. A population-based study. Cancer 2004;101: 51-7.
3. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2009; 27 DOI: 10.1200/JCO.2009.23.8162.
4. Hill TD, Khamis HJ, Tyczynski JE, Berkel H. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 2005;15: 773-80.
5. Anderson WF, Devesa SS. In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer 2005;104: 1733-41.
6. Park S, Kim JH, Koo J, Park BW, Lee KS. Clinicopathological characeristics of male breast cancer. Yonsei Med J 2008;49: 978-86.
7. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published casecontrol studies and discussion of selected aetiological factors. Int J Cancer 1993;53: 538-49.
8. Amir H, Makyawa CK, Moshiro C, Kwesigabo G. Carcinoma of the male breast: a sexually transmitted disease? East Afr Med J 1996;73: 187-90.
9. Nggada HA, Yawe KDT, Abdulazeez J, Khalil MA. Breast cancer burden in Maiduguri. North Eastern Nigeria. Breast J 2008;14: 284-6.
10. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006;367: 595-604.
11. Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast Cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004;83: 77-86.
12. Crew KD, Neugut AI, Wang X, Jacobson JS, Grann VR, Raptis G, et al. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol 2007;25: 1089-98.
13. Gakwaya A, Kigula-Mugambe JB, Kavuma, Luwaga A, Fualal J, Jombwe J, et al. Cancer of the breast : 5-year survival in a tertiary hospital in Uganda. Br J Cancer 2008;99: 63-7.
14. Maalej M, Hentati D, Mesai T, Kochbati L, El May A, Mrad K, et al. Breast cancer in Tunisia in 2004: a comparative Clinical and epidemiological Study. Bull Cancer 2008;95: 5-9.
15. Meguerditchian A, Falardeau M, Martin G. Male breast carcinoma. Can J Surg 2002;45: 296-302.
16. Eser S. Kanser Kayıtçılığı ve Kanser Kayıt Merkezleri. Ed. Tuncer M. Türkiye’de Kanser Kontrolü. T.C. Sağlık Bakanlığı Kanserle Savaş Dairesi Başkanlığı Yayınları, 2007, 47-77.
17. Brinton LA, Richesson DA, Gierach GL, Lacey JV, Park Y, Hollenbeck AR, et al. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 2008;100: 1477-1481.
18. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14: 20-6.
19. Lynch HT, Watson P, Narod SA. The genetic Epidemiology of male breast carcinoma. Cancer 1999;86: 744- 746.
20. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Inter Med 2002;137: 678-687.
21. Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, et al. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 2009;116: 397-400.
22. Chakravarthy A, Kim C. Post-mastectomy radiation in male breast cancer. Radiot Oncol 2002;65: 99-103.
23. Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G. Etiologic factors for male breast cancer in the US Veterans Affairs medical care system database. Breast Cancer Res Treat 2010;119: 185-92.
24. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27: 1250-6.
25. Sanchez AG, Villanueva AG, Redondo C. Lobular carcinoma of the breast in a patient with Klinefelter's syndrome. A case with bilateral, synchronous, histologically different breast tumors. Cancer 1986;57: 1181-3.
26. Koc M, Öztas S, Erem MT, Ciftcioglu MA, Onuk MD. Invasive lobular carcinoma of the male breast: a case report. Jpn J Clin Oncol 2001;31: 444-6.
27. Grabellus F, Worm K, Willruth A, Schmitz KJ, Otterbach F, Baba HA, et al. ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual. Breast 2005;14: 71-4.
28. Niewoehner CB, Schorer AE. Gynaecomastia and breast cancer in men. BMJ 2008;336: 709-13.
29. Chang HL, Kish JB, Smith BL, Goldstein AM. A 16-year-old male with gynecomastia and ductalcarcinoma in situ. Pediatr Surg Int 2008;24: 1251-3.
30. Atalay C, Kanlioz M, Altinok M. Prognostic factors affecting survival in male breast cancer. J Exp Clin Cancer Res 2003;22: 29-33.
31. Koç M, Polat P. Epidemiology and aetiological factors of male breast cancer: a ten years retrospective study in eastern Turkey. Eur J Cancer Prev 2001;10: 531-4.
32. Tynes T. Electromagnetic fields and male breast cancer. Biomed Pharmacother 1993;47: 425-7.
33. Agrawal A, Ayantunde AA, Rampaul R. Male breast cancer: a review of clinical management. Breast Cancer Res Treat 2007;103: 11-21.
34. Dong C, Hemminki K. Second primary breast cancer following breast cancer in men. Breast Cancer Res Treat 2001;66: 171-2.
35. Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 2002;94: 1330-2.
36. Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999;85: 629-39.
37. Vetto J, Jun SY, Padduch D, Eppich H, Shih R. Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg 1999;177: 379-83.
38. Schneider S, Sariego J. Male breast cancer presenting as an axillary mass: a case report and literature review. Southern Med Association 2009;102: 736-7.
39. Ucar AE, Korukluoglu B, Ergul E, Aydin R, Kusdemir A. Bilateral Paget disease of the male nipple: first report. Breast 2008;17: 317-8.
40. Hill A, Yagmur Y, Tran KN, Bolton JS, Robson M, Borgen PI. Localized male breast carcinoma and family history. An analysis of 142 patients. Cancer 1999;86: 821-5.
41. Gunhan-Bilgen I, Bozkaya H, Ustun EE, Memiş A. A male disease: clinial, mamographic and ultrasonographic features. Eur J Radiol 2002;43: 246-55.
42. Chen L, Chantra PK, Larsen LH, Barton P, Rohitopakarn M, Zhu EQ, et al. Imaging characteristics of malignant lesions of the male breast. Radiographics 2006;26: 993-1006.
43. Mathew J, Perkins GH, Stephens T, Middleton LP, Yang WT. Primary breast cancer in men: clinical, imaging, and pathologic findings in 57 patients. AJR 2008;191: 1631-9.
44. Spitz NM, Schild HH, Leutner CC, von Falkenhausen M, Lutterbey G, Kuhl CK. Dynamic contrast-enhanced breast MR imaging in men: Preliminary results. Radiology 2006; 238: 438-445.
45. Hines SL, Tan W, Yasrebi M, DePeri ER, Perez EA. The role of mammography in male patients with breast symptoms. Mayo Clin Proc 2007;82: 297-300.
46. Evans GF, Anthony T, Turnage RH, Schumpert TD, Levy KR, Amirkhan RH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg 2001;181: 96-100.
47. Noguera JJ, Martinez-Miravete P, Idoae F, Diaz L, Pina l, Zornoza G. Metastases to the breast: A review of 33 cases. Aust Radiol 2007;51: 133-8.
48. Burga AM, Fadare O, Lininger RA, Tavassoli FA. Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch 2006;449: 507-12.
49. Macdonald G, Paltiel C, Olivotto IA, Tyldesley S. A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol 2005;16: 1442-8.
50. Cutuli B, Dilhuydy JM, De Lafontan B, Berlie J, Lacroze M, Lesaunier F, et al. Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer 1997;33: 35-8.
51. Goyal A, Horgan K, Kissi M, Yiangou C, Sibbering M, Lansdown M, et al. Sentinel lymph node biopsy in male breast cancer patients. EJSO 2004;30: 480-3.
52. Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, et al. Male breast cancer. Evaluation of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol 2009; doi:10.1016/j.critrevonc. 2009.04.002.
53. Yoney A, Kucuk A, Unsal M. Male breast cancer: a retrospective analysis. Cancer Radiotherapie 2009;13: 103-7.
54. Gentilini O, Chagas E, Zurrida S, Intra C, De Cicco G, Gatti L, et al. Sentinel lymph node biopsy in male patients with early breast cancer. The Oncologist 2007;12: 512-5.
55. Flynn LW, Park J, Patil SM, Cody HS, Port ER. Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. J Am Coll Surg 2008;206: 616-21.
56. Veronesi U, Galimberti V, Mariani, Gatti G, Paganelli G, Viale G, et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 2005;41: 231-7.
57. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23: 7703-20.
58. Atahan L, Yildiz F, Selek U, Sari S, Gurkaynak M. Postoperative radiotherapy in the treatment of male breast carcinoma: a single institute experience. J Nat Med Assoc 2006; 98: 559-63.
59. Gennari R, Curigliano G, Jereczek-Fossa BA, Zurrida S, Renne G, Intra M, et al. Male breast cancer: a special therapeutic problem. Anything new? (Review). Int J Oncol 2004;24: 663-70.
60. Cutuli B. Strategies in treating male breast Cancer. Expert Opin Pharmacother 2007;8: 193-202.
61. Yildirim E, Berberoglu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol 1998;24: 548-52.
62. Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, et al. Adjucant systemic therapy for male breast carcinoma. Cancer 2005;104: 2359-64.
63. Lanitis S, Rice AJ, Vaughan A, Cathcart P, Filippakis G, Mufti RA, et al. Diagnosis and management of male breast cancer. World J Surg 2008;32: 2471-6.
64. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males. A multiinstitutional survey. Cancer 1998; 83: 498-509.
65. Erhan Y, Zekioglu O, Erhan Y. Invaziv lobular carcinoma of the male breast. Can J Surg 2006;49: 365-6.
66. Wittliff JL. Specific receptors of the steroid hormones in breast cancer. Semin Oncol 1974;1: 109-18.
67. Wang-Rodriguez J, Cross K, Gallaher S, Djahanban M, Armstrong JM, Wiedner N, et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002;15: 853-61.
68. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, et al. Molecular markers in male breast carcinoma. Cancer 1998;83: 1947-55.
69. Ferreira M, Mesquita M, Quaresma M, Andre S. Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology 2008;53: 56-61.
70. Perou CM, Sorlie T, Elsen MB, Rijin MV, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
71. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295: 2492-502.
72. Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 2009; doi: 10.1186/bcr2258.
73. Ciocca V, Bombonati A, Gatalica Z, Di Pasquale M, Milos A, Ruiz- Orrico A, et al. Cytokeratin profiles of male breast cancers. Histopathology 2006;49: 365-70.